Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …

There is strong evidence linking venous thromboembolic events and malignancy.
Laboratory markers of coagulation activation such as thrombin–antithrombin complex or …

It has been known for a long time that blood coagulation factor XIII (FXIII) is essential for
maintaining haemostasis, its deficiency leads to severe bleeding complication. Biochemical …

Venous thromboembolism (VTE) is a cardiovascular disorder frequently diagnosed among
cancer patients. Aside from being common, VTE severely deteriorates the prognosis of these …

We investigated the risk factors for venous thrombosis in cancer patients with implantable
ports undergoing chemotherapy. One hundred and seventy one ports were placed in a …

Venous thromboembolism occurs frequently in cancer patients. Two variants in the factor 5
gene (F5), rs6025 encoding for the factor V Leiden mutation R506Q, and rs4524 encoding …

Cancer patients have an increased risk of venous thrombosis (VT). The association of factor
V Leiden (FVL) and the prothrombin 20210A variant with VT in cancer patients is not …

Purpose: We investigated whether the mutant methylenetetrahydrofolate reductase
(MTHFR) increases risk for oral cancer. The common germ-line mutation C677T in the …

Cancer patients have an increased risk of developing venous thromboembolism (VTE), a
condition that is associated with increased morbidity and mortality. Although risk assessment …

Venous thromboembolism (VTE) is a serious and potentially fatal disorder, which is often
associated with a significant impact on the quality of life and on the clinical outcome of …